Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Granuloma, Plasma Cell × ceritinib × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3 Lymphoid 3 CNS 2 Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 3 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Granuloma, Plasma Cell 1 Glioblastoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated

22 enrolled 16 charts

CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡